START-UP 's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical device sectors.
Applied Proteomics brings in $22.5mm through its Series B round
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
